Edinburgh Research Explorer

Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy

Research output: Contribution to journalArticle

  • Russell Hughes
  • Binzhi Qian
  • Charlotte Rowan
  • Munitta Muthana
  • Ioanna Keklikoglou
  • Oakley C Olson
  • Simon Tazzyman
  • Sarah Danson
  • Christina Addison
  • Mark Clemons
  • Ana Maria Gonzalez-Angulo
  • Johanna A Joyce
  • Michele De Palma
  • Jeffrey W Pollard
  • Claire E Lewis

Related Edinburgh Organisations

Open Access permissions

Open

Documents

  • Download as Adobe PDF

    Rights statement: This is the authors' accepted manuscript.

    Accepted author manuscript, 11 MB, PDF-document

http://cancerres.aacrjournals.org/content/75/17/3479.abstract
Original languageEnglish
Pages (from-to)3479-3491
Number of pages13
JournalCancer Research
Volume75
Issue number17
Early online date12 Aug 2015
DOIs
Publication statusPublished - 1 Sep 2015

Abstract

Tumor relapse after chemotherapy-induced regression is a major clinical problem, because it often involves inoperable metastatic disease. Tumor-associated macrophages (TAM) are known to limit the cytotoxic effects of chemotherapy in preclinical models of cancer. Here, we report that an alternatively activated (M2) subpopulation of TAMs (MRC1(+)TIE2(Hi)CXCR4(Hi)) accumulate around blood vessels in tumors after chemotherapy, where they promote tumor revascularization and relapse, in part, via VEGF-A release. A similar perivascular, M2-related TAM subset was present in human breast carcinomas and bone metastases after chemotherapy. Although a small proportion of M2 TAMs were also present in hypoxic tumor areas, when we genetically ablated their ability to respond to hypoxia via hypoxia-inducible factors 1 and 2, tumor relapse was unaffected. TAMs were the predominant cells expressing immunoreactive CXCR4 in chemotherapy-treated mouse tumors, with the highest levels expressed by MRC1(+) TAMs clustering around the tumor vasculature. Furthermore, the primary CXCR4 ligand, CXCL12, was upregulated in these perivascular sites after chemotherapy, where it was selectively chemotactic for MRC1(+) TAMs. Interestingly, HMOX-1, a marker of oxidative stress, was also upregulated in perivascular areas after chemotherapy. This enzyme generates carbon monoxide from the breakdown of heme, a gas known to upregulate CXCL12. Finally, pharmacologic blockade of CXCR4 selectively reduced M2-related TAMs after chemotherapy, especially those in direct contact with blood vessels, thereby reducing tumor revascularization and regrowth. Our studies rationalize a strategy to leverage chemotherapeutic efficacy by selectively targeting this perivascular, relapse-promoting M2-related TAM cell population.

Download statistics

No data available

ID: 21761952